Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S W Tan

Showing results (301-310 of 317) with videos related to

Pageof 32
Sort By:
Nature|May 18, 2018
Bystander CD8<sup>+</sup> T cells are abundant and phenotypically distinct in human tumour infiltratesYannick Simoni, Etienne Becht, Michael Fehlings, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Immunity|December 18, 2016
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and FrequencyYannick Simoni, Michael Fehlings, Henrik N Kløverpris, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
JTO Clinical and Research Reports|November 25, 2022
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLCGillianne G Y Lai, Jia Chi Yeo, Amit Jain, et al.
Nature Communications|August 14, 2019
Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stagesAdeline C Y Chua, Jessica Jie Ying Ong, Benoit Malleret, et al.
Progress in Retinal and Eye Research|September 26, 2025
International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME)Danny S C Ng, Paisan Ruamviboonsuk, Rajendra S Apte, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Pageof 32

Showing results (301-310 of 317) with videos related to

Sort By:
Pageof 32
Nature|May 18, 2018
Bystander CD8<sup>+</sup> T cells are abundant and phenotypically distinct in human tumour infiltratesYannick Simoni, Etienne Becht, Michael Fehlings, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Immunity|December 18, 2016
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and FrequencyYannick Simoni, Michael Fehlings, Henrik N Kløverpris, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
JTO Clinical and Research Reports|November 25, 2022
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLCGillianne G Y Lai, Jia Chi Yeo, Amit Jain, et al.
Nature Communications|August 14, 2019
Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stagesAdeline C Y Chua, Jessica Jie Ying Ong, Benoit Malleret, et al.
Progress in Retinal and Eye Research|September 26, 2025
International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME)Danny S C Ng, Paisan Ruamviboonsuk, Rajendra S Apte, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Pageof 32